What's Happening?
LEO Pharma has presented new 12-month real-world data for its drug tralokinumab at the American Academy of Dermatology 2026 meeting. The data from the TRACE study shows that tralokinumab significantly reduces the severity of atopic dermatitis (AD) and
improves the quality of life for patients, including those with skin of color and hand and foot involvement. The study involved 824 adult patients and demonstrated that nearly all patients achieved at least one moderate treatment target. The drug is approved for use in several countries, including the U.S., for treating moderate-to-severe AD in patients aged 12 and older.
Why It's Important?
The positive results from the TRACE study highlight tralokinumab's potential as an effective treatment for atopic dermatitis, a chronic inflammatory skin condition. This could lead to improved management of AD, particularly in diverse patient populations and those with challenging areas of involvement. The findings may influence treatment guidelines and encourage broader adoption of tralokinumab in clinical practice, potentially improving outcomes for millions of AD patients worldwide. Additionally, the study underscores the importance of real-world data in understanding the effectiveness of treatments across different patient demographics.
